<DOC>
	<DOCNO>NCT01280565</DOCNO>
	<brief_summary>Masitinib novel TKI potently inhibit wild type ( WT ) c-kit activated form , mutate juxtamembrane region ( JM c-kit ) PDGFRs , intracellular kinase Lyn , less extent fibroblast growth factor receptor 3 ( FGFR3 ) . Pre-clinical data suggest masitinib strong candidate treatment patient advance melanoma carry c-kit JM mutation .</brief_summary>
	<brief_title>A Phase 3 Study Compare Efficacy Safety Masitinib Dacarbazine Treatment Patients With Non-Resectable Metastatic Stage 3 Stage 4 Melanoma Carrying Mutation Juxta Membrane Domain C-Kit</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patient histologically cytologically confirm nonresectable metastatic stage 3 ( nonresectable IIIB IIIC , AJCC TNM stag system 7th edition ) stage 4 melanoma Patient detectable ckit JM mutation confirm DNA RNA sequencing , expect mainly find screen mucosal acral melanoma melanoma skin chronic suninduced damage ( define microscopically marked elastosis involve skin surround primary melanoma ) Patient measurable disease accord RECIST Patient ECOG ≤ 2 Patient malignancy patient continuously diseasefree &lt; 3 year , exception melanoma , cervical carcinoma situ , basal cell squamous cell skin cancer , ductal lobular carcinoma situ breast Patient active brain metastasis eligible . Patients treat brain metastasis eligible : presence 3 brain lesion le lesion ( ) diameter ≤ 2 cm radiation therapy ( gamma knife ) complete ≥ 4 week prior baseline surgery complete ≥4 week prior baseline lesion assess followup scan ( MRI MRI perform brain therapy ) ≥ 1 month brain therapy consider control baseline Patient refractory dacarbazine define patient present disease progression 3 month dacarbazine therapy . Prior treatment tyrosine kinase ckit inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>non-resectable metastatic stage 3 stage 4 melanoma carry mutation juxta membrane domain c-kit</keyword>
</DOC>